Compare McKesson Corporation (MCK) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Payoneer Global Inc — how do they compare? McKesson Corporation trades at $824.07 (market cap $97.35B), while Payoneer Global Inc trades at $7.11 (market cap $2.41B). The key difference: McKesson Corporation is far larger — about 40.4× Payoneer Global Inc's market cap, and McKesson Corporation pays a 0.39% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| MCK | PAYO | |
|---|---|---|
Market Cap | $97.35B | $2.41B |
Sector | Health | Technology |
52-Week High | $995.69 | $7.42 |
52-Week Low | $659.01 | $4.27 |
Enterprise Value | $101.98B | $2.15B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Payoneer (PAYO) trades at $7.125, up 0.07% today, with a strong technical outlook as moving averages signal bullish momentum. The company reported revenue of $821.16M in 2025, with a net income margin of 8.57%, though earnings have shown volatility with recent beats and misses. Recent news highlights a pending $2.75 billion acquisition by Nuvei, announced June 15, 2026, which has driven significant investor attention and legal scrutiny over the fairness of the $7.40 per share offer.
The acquisition by Nuvei presents a near-term catalyst, but shareholder lawsuits question the deal price. Analyst consensus is bullish with a $8.20 price target, yet execution risks and integration challenges post-acquisition could impact long-term value. Investors should weigh the premium offered against potential standalone growth prospects in the competitive fintech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
